Cited by 2,770Cancer Cells and MetastasisDrug Transport and Resistance MechanismsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 183 of the 188 references it cites were found in a registry or an index.

A view on drug resistance in cancer

Open access

Vasan, Neil, Baselga, José, Hyman, David M.·2019·Nature

DOI 10.1038/s41586-019-1730-1PMC PMC8008476

Open this paper in CoChat — free account Open PDF

Abstract

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. These different approaches could eventually be synthesized for each tumour at any decision point and used to inform the choice of therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1730-1

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression.
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

Show all 188 references

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 901–1,000 of 1,001

Exosomal MiRNAs in Osteosarcoma: Biogenesis and Biological Functions
Tang, J., He, J., Feng, C., & Tu, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.902049 · Cited by 17
A Novel Late-Stage Autophagy Inhibitor That Efficiently Targets Lysosomes Inducing Potent Cytotoxic and Sensitizing Effects in Lung Cancer
Molero-Valenzuela, A., Fontova, P., Alonso-Carrillo, D., Carreira‐Barral, I., Torres, A. A., García‐Valverde, M., Benítez-García, C., Pérez‐Tomás, R., Quesada, R., & Soto‐Cerrato, V. (2022) · Cancers · doi:10.3390/cancers14143387 · Cited by 17
Publication trends and hotspots of drug resistance in colorectal cancer during 2002-2021: A bibliometric and visualized analysis
Zhao, P., Jiao, Y.-N., Ma, Z.-F., Yang, Y., Li, Y., Hu, S.-D., Li, S.-Y., & Du, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.947658 · Cited by 17
Identifying Hub Genes Associated with Neoadjuvant Chemotherapy Resistance in Breast Cancer and Potential Drug Repurposing for the Development of Precision Medicine
Saha, T., Detroja, R., Mukherjee, S., & Samson, A. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012628 · Cited by 16
EGFL7 drives the evolution of resistance to EGFR inhibitors in lung cancer by activating NOTCH signaling
Wang, Y., Chen, P., Zhao, M., Cao, H., Zhao, Y., Ji, M., Hou, P., & Chen, M. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05354-y · Cited by 17
The multifaceted role of MUC1 in tumor therapy resistance
Jin, W., Zhang, M., Dong, C., Huang, L. H., & Luo, Q. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00978-y · Cited by 17
Cancer Antigen 125 Expression Enhances the Gemcitabine/Cisplatin-Resistant Tumor Microenvironment in Bladder Cancer
Yamashita, T., Higashi, M., Sugiyama, H., Morozumi, M., Momose, S., & Tamaru, J. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.12.005 · Cited by 17
Therapeutic Effects of Natural Products Isolated from Different Microorganisms in Treating Cervical Cancer: A Review
Mukherjee, D., Lahiri, D., & Nag, M. (2022) · Cancer Insight · doi:10.58567/ci01020003 · Cited by 17
Interaction study with DNA/HSA, anti-topoisomerase IIα, cytotoxicity and in vitro antiproliferative evaluations and molecular docking of indole-thiosemicarbazone compounds
Jacob, Í. T. T., Filho, I. J. D. C., Alves, J. E. F., Souza, F. D. M., de Azevedo, R. D. S., Marques, D. S. C., Souza, T. R. C. D. L., dos Santos, K. L., Pitta, M. G. D. R., Rêgo, M. J. B. D. M., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123606 · Cited by 17
Cytotoxic Activity, Anti-Migration and In Silico Study of Black Ginger (Kaempferia parviflora) Extract against Breast Cancer Cell
Hairunisa, I., Bakar, M. F. A., Da’i, M., Bakar, F. I. A., & Syamsul, E. S. (2023) · Cancers · doi:10.3390/cancers15102785 · Cited by 17
Applying thermodynamics as an applicable approach to cancer diagnosis, evaluation, and therapy: A review
Shamsabadipour, A., Pourmadadi, M., Davodabadi, F., Rahdar, A., & Ferreira, L. F. R. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104681 · Cited by 19
Bibliometric and visual analysis in the field of traditional Chinese medicine in cancer from 2002 to 2022
Bai, F., Huang, Z., Luo, J., Qiu, Y., Huang, S., Huang, C., Liu, T., Zhang, H., & Wang, D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1164425 · Cited by 17
β-HB treatment reverses sorafenib resistance by shifting glycolysis–lactate metabolism in HCC
Suk, F., Wu, C.-Y., Fang, C.-C., Chen, T.-L., & Liao, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115293 · Cited by 19
TNFR2 promotes pancreatic cancer proliferation, migration, and invasion via the NF-κB signaling pathway
Gao, Z., Zhang, Q., Chen, H., Chen, J., Kang, J., Yu, H. J., Song, Y., & Zhang, X. (2023) · Aging · doi:10.18632/aging.204941 · Cited by 17
Chemoresistant fibroblasts dictate neoadjuvant chemotherapeutic response of head and neck cancer via TGFα-EGFR paracrine signaling
Su, L., Wu, S., Huang, C., Zhuo, X., Chen, J., Jiang, X., Kong, X., Lv, C., Xu, Q., Han, P., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00460-2 · Cited by 20
Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway
Huang, Y., Wang, S., Zhang, X., Yang, C. G., Wang, S., Cheng, H., Ke, A., Gao, C., & Guo, K. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107082 · Cited by 17
Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers
Mauri, G., Patelli, G., Roazzi, L., Valtorta, E., Amatu, A., Marrapese, G., Bonazzina, E. F., Tosi, F., Bencardino, K. B., Ciarlo, G., et al. (2024) · Journal of Clinical Pathology · doi:10.1136/jcp-2023-209341 · Cited by 19
Liposomal Nano-Based Drug Delivery Systems for Breast Cancer Therapy: Recent Advances and Progresses
Yazdan, M., Naghib, S. M., & Moepubi, M. R. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206293653240322041047 · Cited by 18
Nuclear factor-κB activation by transforming growth factor-β1 drives tumour microenvironment-mediated drug resistance in neuroblastoma
Louault, K., Blavier, L., Lee, M., Kennedy, R. J., Fernández, G. E., Pawel, B., Asgharzadeh, S., & DeClerck, Y. A. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02686-8 · Cited by 18
Context-dependent T-BOX transcription factor family: from biology to targeted therapy
Li, S., Luo, X., Sun, M., Wang, Y., Zhang, Z., Jiang, J., Hu, D., Zhang, J., Wu, Z., Wang, Y., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01719-2 · Cited by 18
FXN targeting induces cell death in ovarian cancer stem-like cells through PRDX3-Mediated oxidative stress
Xu, S., Liu, Y., Yang, S., Fei, W., Qin, J., Lü, W., & Xu, J. (2024) · iScience · doi:10.1016/j.isci.2024.110506 · Cited by 17
SIRT1 promotes doxorubicin‐induced breast cancer drug resistance and tumor angiogenesis via regulating GSH‐mediated redox homeostasis
Sahoo, S., Kumari, S., Pulipaka, S., Chandra, Y., & Kotamraju, S. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23809 · Cited by 19
Phytosome-based nanotechnology for enhanced efficacy of anticancer phytocompounds: Challenges and prospects
Sadr, S., Hajjafari, A., Lotfalizadeh, N., Lotfalizadeh, M., Laein, S. S., Abbasi, A. M., Jafroodi, P. P., Moghadam, E. R. A., Rahdar, A., Fathi‐karkan, S., et al. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106543 · Cited by 17
Cancer immunotherapy in progress—an overview of the past 130 years
Ikeda, H. (2025) · International Immunology · doi:10.1093/intimm/dxaf002 · Cited by 20
Exploring near-infrared absorbing nanocarriers to overcome cancer drug resistance
Chu, S., & Stochaj, U. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.20 · Cited by 16
Targeting Epigenetic ‘Readers’ with Natural Compounds for Cancer Interception
Damiani, E., Duran, M., Mohan, N., Rajendran, P., & Dashwood, R. H. (2020) · Journal of Cancer Prevention · doi:10.15430/jcp.2020.25.4.189 · Cited by 17
TUFT1 Facilitates Metastasis, Stemness, and Vincristine Resistance in Colorectal Cancer via Activation of PI3K/AKT Pathway
Yang, Y., Zhang, T., & Wu, L. (2021) · Biochemical Genetics · doi:10.1007/s10528-021-10051-0 · Cited by 17
MicroRNA-32 and MicroRNA-548a Promote the Drug Sensitivity of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting ROBO1 and Inhibiting the Activation of Wnt/β-Catenin Axis
Zheng, J., Li, X., Cai, C., Hong, C., & Zhang, B. (2021) · Cancer Management and Research · doi:10.2147/cmar.s295003 · Cited by 17
Anticancer and Antimicrobial Activity Evaluation of Cowpea-Porous-Starch-Formulated Silver Nanoparticles
Ramdath, S., Mellem, J. J., & Mbatha, L. S. (2021) · Journal of Nanotechnology · doi:10.1155/2021/5525690 · Cited by 17
Sonochemical synthesis of 2-substituted nicotinic acid ethyl ester derivatives: Their in vitro and in silico evaluation against SIRT1
Challa, C. S., Katari, N. K., Nallanchakravarthula, V., Nayakanti, D., Kapavarapu, R., & Pal, M. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131069 · Cited by 17
A self-expandable C-shaped 3D printing tracheal stent for combinatorial controlled paclitaxel release and tracheal support
Chen, Z., Jin, Z., Yang, L., Liu, Y., Liu, J., Cai, S., Shen, Y., & Guo, S. (2022) · Materials Today Chemistry · doi:10.1016/j.mtchem.2021.100760 · Cited by 17
MicroRNAs as the Critical Regulators of Forkhead Box Protein Family in Pancreatic, Thyroid, and Liver Cancers
Akhlaghipour, I., Fanoodi, A., Zangouei, A. S., Taghehchian, N., Khalili‐Tanha, G., & Moghbeli, M. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10346-4 · Cited by 17
Principles of ecDNA random inheritance drive rapid genome change and therapy resistance in human cancersPreprint
Lange, J. T., Chen, C. Y., Pichugin, Y., Xie, L., Tang, J., Hung, K. L., Yost, K. E., Shi, Q., Erb, M. L., Rajkumar, U., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.11.447968 · Cited by 17
A multiplex, prime editing framework for identifying drug resistance variants at scalePreprint
Chardon, F. M., Suiter, C. C., Daza, R. M., Smith, N. T., Parrish, P. C. R., McDiarmid, T. A., Lalanne, J., Martin, B., Calderon, D., Ellison, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.27.550902 · Cited by 17
In situ metabolic Characterisation of Breast Cancer and its Potential Impact on Therapy
Petővári, G., Dankó, T., Tőkés, A.-M., Vetlényi, E., Krencz, I., Raffay, R., Hajdu, M., Sztankovics, D., Németh, K., Vellai-Takács, K., et al. (2020) · Cancers · doi:10.3390/cancers12092492 · Cited by 16
Unlocking the Power of Photothermal Agents: A Universal Platform for Smart Immune NIR‐Agonists for Precise Cancer Therapy
Zhang, H., Xu, X., Cao, Y., Chen, Z., Liu, W., Lu, X., & Li, C. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202424830 · Cited by 16
Recent Advances in Smart Linkage Strategies for Developing Drug Conjugates for Targeted Delivery
Zhang, J., Yang, Z., Liu, Y., Liu, Y., Qu, J., & Pan, X. (2025) · Topics in Current Chemistry · doi:10.1007/s41061-025-00497-w · Cited by 16
Microplastics promote chemoresistance by mediating lipid metabolism and suppressing pyroptosis in colorectal cancer
Hu, D., Liu, H., Guo, Y., Zhang, H., Qiu, M., Yang, Z., Hao, J., Jiang, Z., Gao, M., Zhang, X., et al. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02143-8 · Cited by 16
Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies
Li, H., Xu, W., Cheng, W., Yu, G., & Tang, D. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1612089 · Cited by 17
Roles and mechanisms of NSUN2-mediated RNA m5C modification in cancer progression and immune modulation
Li, C.-H., Yuan, Y.-X., Jiang, X.-L., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1702436 · Cited by 15
The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies
Attili, I., Re, M. D., Guerini‐Rocco, E., Crucitta, S., Pisapia, P., Pepe, F., Barberis, M. C. P., Troncone, G., Danesi, R., de Marinis, F., et al. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1943365 · Cited by 17
Exosomes-mediated tumor treatment: One body plays multiple roles
Xu, N., Guo, R., Yang, X., Li, N., Yu, J., & Zhang, P. (2021) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.08.003 · Cited by 16
Transition metal-catalyzed Synthesis of New 3-substituted Coumarin Derivatives As Antibacterial and Cytostatic Agents
Sokol, I., Toma, M., Krnić, M., Meščić, A., Drenjančević, D., Liekens, S., Raić‐Malić, S., & Kraljević, T. G. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0161 · Cited by 16
Quaternary Ammonium Salts Anchored on Cross-Linked ( R )-(+)-Lipoic Acid Nanoparticles for Drug-Resistant Tumor Therapy
Zhou, X., Dai, X., Tan, J., Wu, X., Zhou, X., Liao, C., & Zhang, S. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c16293 · Cited by 16
Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy
Wang, W., Sun, Y., Liu, X., Kumar, S. K., Jin, F., & Dai, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.859455 · Cited by 16
Self-Assembly of Small Organic Molecules into Luminophores for Cancer Theranostic Applications
Wang, J., Wang, X., Yang, K. H., Hu, S., & Wang, W. (2022) · Biosensors · doi:10.3390/bios12090683 · Cited by 16
Pegylated Curcumin Derivative: Water-Soluble Conjugates with Antitumor and Antibacterial Activity
Yakub, G., Manolova, N. E., Rashkov, I. B., Markova, N., Toshkova, R. A., Georgieva, A. K., Mincheva, R., Toncheva, A., Raquez, J., & Dúbois, P. (2022) · ACS Omega · doi:10.1021/acsomega.2c04173 · Cited by 16
Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy
Katopodi, T., Petanidis, S., Tsavlis, D., Anestakis, D., Charalampidis, C., Chatziprodromidou, I. P., Eskitzis, P., Zarogoulidis, P., Kosmidis, C. S., Matthaios, D., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1042125 · Cited by 17
Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape
Uliano, J., Nicolò, E., Corvaja, C., Salimbeni, B. T., Trapani, D., & Curigliano, G. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2142559 · Cited by 16
TRPV4 Promotes Metastasis in Melanoma by Regulating Cell Motility through Cytoskeletal Rearrangement
Huang, S., Yu, S., Deng, R., Liu, H., Ding, Y., Sun, Y., Chen, W., Wang, A., Wei, Z., & Lu, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315155 · Cited by 16
A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer
Wang, L., Xiao, K., Dong, Z., Meng, T., Cheng, X., & Xu, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04916-7 · Cited by 16
CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis
Kim, J. S., Shin, M. J., Lee, S. Y., Kim, D. K., Choi, K. U., Suh, D. S., Kim, D., & Kim, J. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210306 · Cited by 16
Extracellular cell matrix stiffness-driven drug resistance of breast cancer cells via EGFR activation
Li, T., Li, Y., Wu, H., Peng, C., Wang, J., Chen, S., Zhao, T., Li, S., Qin, X., & Liu, Y. (2023) · Mechanobiology in Medicine · doi:10.1016/j.mbm.2023.100023 · Cited by 18
Nanosponge-mediated oligonucleotide delivery: A cutting-edge technology towards cancer management
Khairnar, P., Kolipaka, T., Pandey, G., Phatale, V., Shah, S., Srinivasarao, D. A., Saraf, S., & Srivastava, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105226 · Cited by 16
Research progress of exosomes in drug resistance of breast cancer
Liu, L., Jiang, D., Bai, S., Zhang, X., & Kang, Y. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1214648 · Cited by 17
Exosomes: A Cutting-Edge Theranostics Tool for Oral Cancer
Kalele, K., Nyahatkar, S., Mirgh, D., Muthuswamy, R., Adhikari, M. D., & Anand, K. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c01243 · Cited by 16
Time-Resolved Ultraviolet Photodissociation Mass Spectrometry Probes the Mutation-Induced Alterations in Protein Stability and Unfolding Dynamics
Luo, P., Liu, Z., Lai, C., Jin, Z., Wang, M., Zhao, H., Liu, Y., Zhang, W., Wang, X., Xiao, C., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c00316 · Cited by 16
Reversing Anticancer Drug Resistance by Synergistic Combination of Chemotherapeutics and Membranolytic Antitumor β-Peptide Polymer
Shao, N., Yuan, L., Liu, L., Cong, Z., Wang, J., Wu, Y., & Liu, R. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c00434 · Cited by 17
Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors
Choi, J., Shin, J. H., Kim, T. K., Kim, K., Kim, J.-Y., Jeon, E., Park, J., Han, Y. D., Kim, K., Sim, T., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216904 · Cited by 19
Biological clock regulation by the PER gene family: a new perspective on tumor development
Chen, K., Wang, Y., Li, D., Wu, R., Wang, J., Wei, W., Zhu, W., Xie, W., Feng, D., & He, Y. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1332506 · Cited by 16
Recent advanced lipid-based nanomedicines for overcoming cancer resistance
Dechbumroong, P., Hu, R., Keaswejjareansuk, W., Namdee, K., & Liang, X. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.19 · Cited by 18
Role of cell division cycle-associated proteins in regulating cell cycle and promoting tumor progression
Wang, Z., Ren, M., Liu, W., Wu, J., & Tang, P. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189147 · Cited by 16
Terpenoids from quinoa reverse drug resistance of colon cancer by upregulating miR ‐495‐3p
Feng, M., Fan, X., Shi, J., Shan, S., Li, S., He, S., Ding, M., & Li, Z. (2024) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.13718 · Cited by 16
Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing
Zhang, J., Xu, X., Deng, H., Liu, L., Xiang, Y., & Feng, J. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108697 · Cited by 18
Synthesis, characterization and application of hydrogel for cancer treatment
Jain, N., Kejariwal, M., Chowdhury, F. I., Noor, I. M., Savilov, S. V., Yahya, M. Z. A., Diantoro, M., & Singh, P. K. (2024) · Chemical Physics Impact · doi:10.1016/j.chphi.2024.100737 · Cited by 16
Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems
Perra, M., Castangia, I., Aroffu, M., Fulgheri, F., Rached, R. A., Manca, M. L., Cortés, H., Prado-Audelo, M. L. D., Nomura-Contreras, C. A., Romero‐Montero, A., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-01820-z · Cited by 16
The Impact of Polyunsaturated Fatty Acids in Cancer and Therapeutic Strategies
Yan, D., Hou, Y., Lei, X., Xiao, H., Zeng, Z., Xiong, W., & Fan, C. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00639-y · Cited by 18
mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers.
Li, F., Guo, E., Huang, J. M., Lu, F., Yang, B., Xiao, R., Liu, C., Wu, X. Y., Fu, Y., Wang, Z., et al. (2020) · PubMed Central · Cited by 16
Progress of long noncoding RNAs in anti-tumor resistance
Zhang, H., Wang, Y., Liu, X., & Li, Y. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153215 · Cited by 16
The Roles of CircRNAs in Bladder Cancer: Biomarkers, Tumorigenesis Drivers, and Therapeutic Targets
Cheng, F., Zheng, B., Si, S., Wang, J., Zhao, G., Yao, Z., Niu, Z., & He, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.666863 · Cited by 16
Microbial Lipopeptide Supramolecular Self‐Assemblies as a Methuosis‐Like Cell Death Inducer with In Vivo Antitumor Activity
Lu, J., Huang, W. T., Zhou, K., Zhao, X., Yang, S., Xia, L., & Ding, X. (2021) · Small · doi:10.1002/smll.202104034 · Cited by 16
KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies
Naim, N., Moukheiber, S., Daou, S., & Kourié, H. R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103524 · Cited by 16
Cancer Conformational Landscape Shapes Tumorigenesis
Bamberger, C., Diedrich, J. K., Martínez‐Bartolomé, S., & Yates, J. R. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00906 · Cited by 16
Therapeutic Potential of Natural Products in the Treatment of Renal Cell Carcinoma: A Review
Feng, C., Lyu, Y., Gong, L., & Wang, J. (2022) · Nutrients · doi:10.3390/nu14112274 · Cited by 16
Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers
Yung, M. M. H., Siu, M. K. Y., Ngan, H., Chan, D. W., & Chan, K. K. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126857 · Cited by 18
Dot extrusion bioprinting of spatially controlled heterogenous tumor models
Wei, X., Huang, B., Chen, K., Fan, Z., Wang, L., & Xu, M. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.111152 · Cited by 16
State-of-the-art: MXene structures in nano-oncology
Manisekaran, R., Chettiar, A. R., Kandasamy, G., García‐Contreras, R., & Acosta‐Torres, L. S. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213354 · Cited by 16
In situ valence-transited arsenic nanosheets for multi-modal therapy of colorectal cancer
Zheng, H., Zhang, K., Piao, J., Mu, C., Xie, X., Cheng, M., Yue, T., Sun, J., Li, B., Wei, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57376-7 · Cited by 15
The Role of Medicinal Plants in Modulating Epigenetic Mechanisms: Implications for Cancer Prevention and Therapy
Bendrihem, K. A., Mouane, A., Azzi, M., Mihoubi, M. A., Atanassova, M., SAWICKA, B. H., Zahnit, W., & Messaoudi, M. (2025) · Phytotherapy Research · doi:10.1002/ptr.8481 · Cited by 16
Sequence-defined polymers for biomedical applications
Jäck, N., Nagel, S., & Hartmann, L. (2025) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2025.101993 · Cited by 16
USP5 regulates ferroptosis in colorectal cancer by targeting the YBX3/SLC7A11 axis through lysosomal degradation
Qiu, H.-W., Liu, Y., Zhou, H.-M., Hu, L.-J., Qi, W., Ma, H., Liu, Y.-Y., Li, L., Yang, N., Huang, M.-Q., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08146-2 · Cited by 15
MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors
Angerilli, V., Galuppini, F., Businello, G., Santo, L. D., Savarino, E. V., Realdon, S., Guzzardo, V., Nicolè, L., Lazzarin, V., Lonardi, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9030318 · Cited by 16
Thermodynamic Genome-Scale Metabolic Modeling of Metallodrug Resistance in Colorectal Cancer
Herrmann, H. A., Rusz, M., Baier, D., Jakupec, M. A., Keppler, B. K., Berger, W., Koellensperger, G., & Zanghellini, J. (2021) · Cancers · doi:10.3390/cancers13164130 · Cited by 15
LGCMDS: Predicting miRNA-Drug Sensitivity based on Light Graph Convolution Network
Yu, S., Xu, H., Li, Y., Liu, D., & Deng, L. (2021) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm52615.2021.9669566 · Cited by 15
Ultrasound-induced cavitation and passive acoustic mapping: SonoTran platform performance and short-term safety in a large-animal model
Masiero, M., Boulos, P. B., Crake, C., Rowe, C., & Coviello, C. M. (2022) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2022.03.010 · Cited by 15
Modulated plasmonic nanofibrous scaffold reinforced breast cancer photo-ablation and breast neurotization with resensation
Jaswal, R., Kaliannagounder, V. K., Kumar, D., Park, C. H., & Kim, C. S. (2022) · Composites Part B Engineering · doi:10.1016/j.compositesb.2022.110129 · Cited by 15
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
Atkins, M. B., Abu‐Sbeih, H., Ascierto, P. A., Bishop, M., Chen, D. S., Dhodapkar, M. V., Emens, L. A., Ernstoff, M. S., Ferris, R. L., Greten, T. F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005413 · Cited by 15
Genomic Landscape and Potential Regulation of RNA Editing in Drug Resistance
Zhou, X., Mitra, R., Hou, F., Zhou, S., Wang, L., & Jiang, W. (2023) · Advanced Science · doi:10.1002/advs.202207357 · Cited by 15
The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases
Hu, X., Liu, X., Khatri, U., & Wu, J. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100958 · Cited by 15
Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model
Vinogradov, A. E., & Anatskaya, O. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076196 · Cited by 15
Anthelmintic Drugs as Emerging Immune Modulators in Cancer
Stolfi, C., Pacifico, T., Luiz-Ferreira, Â., Monteleone, G., & Laudisi, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076446 · Cited by 19
Identification of associations between lncRNA and drug resistance based on deep learning and attention mechanism
Gao, M., & Shang, X. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1147778 · Cited by 15
Cellular barcoding: From developmental tracing to anti-tumor drug discovery
Wang, Y., Zhang, X., & Wang, Z. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216281 · Cited by 16
Nothing makes sense in drug resistance except in the light of evolution
Gabaldón, T. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2023.102350 · Cited by 15
A cycloruthenated complex, ruthenium (II) Z (RuZ) overcomes in vitro and in vivo multidrug resistance in cancer cells: A pivotal breakthrough
Cao, L., Xie, Y., Chen, Z., & Ashby, C. R. (2023) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0081 · Cited by 15
Predicting circRNA-Drug Resistance Associations Based on a Multimodal Graph Representation Learning Framework
Liu, Z., Dai, Q., Yu, X., Duan, X., & Wang, C. (2023) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2023.3299423 · Cited by 15
A multivariate metal–organic framework based pH-responsive dual-drug delivery system for chemotherapy and chemodynamic therapy
Akbar, M. U., Akbar, A., Saddozai, U. A. K., Khan, M. I. U., Zaheer, M., & Badar, M. (2023) · Materials Advances · doi:10.1039/d3ma00389b · Cited by 15
Synthetic and pharmacological developments in the hybrid s-triazine moiety: A review
Bareth, D., Jain, S., Kumawat, J., Kishore, D., Dwivedi, J., & Hashmi, S. Z. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106971 · Cited by 15
Game Theory for Managing Evolving Systems: Challenges and Opportunities of Including Vector-Valued Strategies and Life-History Traits
Kleshnina, M., Streipert, S., Brown, J. S., & Staňková, K. (2023) · Dynamic Games and Applications · doi:10.1007/s13235-023-00544-5 · Cited by 15
Harnessing atomic force microscopy‐based single‐cell analysis to advance physical oncology
Li, M. (2023) · Microscopy Research and Technique · doi:10.1002/jemt.24467 · Cited by 16

Authors: Vasan, N., Baselga, J., & Hyman, D. M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Hyman, David M.
ORCID: Vasan, Neil
Hyman, David M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2019-11-13
Volume: 575
Issue: 7782
Pages: 299-309
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-019-1730-1
PMC: PMC8008476
OpenAlex: W2988773550
Cited by: 2,770
References: 188
Citations by year: 2026: 344 · 2025: 533 · 2024: 524 · 2023: 467 · 2022: 397 · 2021: 346 · 2020: 150 · 2019: 4
FWCI: 21.44
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Eli Lilly and Company
National Cancer Institute (R01CA207244, R01CA190642, P30CA008748, T32CA009207)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: chemoresistance, tumor heterogeneity, tumor microenvironment, tumor immune evasion, tumor growth kinetics, tumor burden, early cancer detection, adaptive monitoring, synthetic lethality screen, precision oncology
MeSH terms: Antineoplastic Agents, Humans, Models, Biological, Neoplasms, Drug Resistance, Neoplasm, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A view on drug resistance in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks